Throughout the last three months, 4 analysts have evaluated Maravai LifeSciences (NASDAQ:MRVI), offering a diverse set of opinions from bullish to bearish.

In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $8.31, with a high estimate of $13.00 and a low estimate of $4.25. Highlighting a 20.86% decrease, the current average has fallen from the previous average price target of $10.50.

Understanding Analyst Ratings: A Comprehensive Breakdown

The perception of Maravai LifeSciences by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Capture valuable insights into Maravai LifeSciences's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.

Stay up to date on Maravai LifeSciences analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

About Maravai LifeSciences

Maravai LifeSciences: A Financial Overview

Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.

Revenue Growth: Maravai LifeSciences's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -2.49%. This indicates a decrease in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.

Net Margin: Maravai LifeSciences's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -151.9%, the company may encounter challenges in effective cost control.

Return on Equity (ROE): Maravai LifeSciences's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -25.33%, the company may face hurdles in achieving optimal financial returns.

Return on Assets (ROA): Maravai LifeSciences's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -7.27%, the company may face hurdles in generating optimal returns from its assets.

Debt Management: With a high debt-to-equity ratio of 1.63, Maravai LifeSciences faces challenges in effectively managing its debt levels, indicating potential financial strain.

The Basics of Analyst Ratings

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.

Breaking: Wall Street's Next Big Mover

Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.

This article was generated by Benzinga's automated content engine and reviewed by an editor.